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Abstract
Purpose Androgen receptor (AR) expression occurs in up to 86% of human epidermal growth factor receptor 2-positive
(HER2+) breast cancers. In vitro, AR inhibitors enhance antitumor activity of trastuzumab, an anti-HER2 antibody, in trastuzumab-resistant HER2+ cell lines. This open-label, single-arm, phase II study evaluated the efficacy and safety of enzalutamide, an AR-signaling inhibitor, in patients with advanced HER2+ AR+ breast cancer previously treated with trastuzumab.
Methods Eligible patients had measurable or non-measurable evaluable disease per Response Evaluation Criteria in Solid
Tumors (RECIST) v1.1, Eastern Cooperative Oncology Group status ≤ 1, no history of brain metastases, and previously
received ≥ 1 anti-HER2 regimen for advanced disease. Patients received 160 mg oral enzalutamide daily and 6 mg/kg intravenous trastuzumab every 21 days until disease progression or unacceptable toxicity. Primary end point was clinical benefit
rate at 24 weeks (CBR24); secondary end points included progression-free survival (PFS) and safety.
Results Overall, 103 women were enrolled [median age 60 years (range 34–83)]; 62% had received ≥ 3 lines of prior antiHER2 therapy. CBR24, comprising patients with confirmed partial responses (5%) and durable stable disease at 24 weeks
(19%), was 24% in the efficacy evaluable set (n = 89). CBR24 did not seem related to AR-expression levels or hormone
receptor status. Median PFS was 3.4 months (95% confidence interval 2.0–3.8). Overall, 97 (94%) patients experienced
treatment-emergent adverse events (TEAEs), with fatigue most common (34%). Dyspnea (4%) and malignant neoplasm
progression (3%) were the only TEAEs grade ≥ 3 reported in ≥ 3 patients. 22 patients (21%) reported serious TEAEs. Four
patients (4%) experienced fatal, non-drug-related TEAEs.
Conclusions Enzalutamide plus trastuzumab was well tolerated, and a subset of patients in this heavily pretreated population had durable disease control. Determination of biomarkers is needed to identify patients most likely to benefit from this
combination.
ClinicalTrials.gov number NCT02091960
Keywords Androgen receptor · Enzalutamide · HER2 · Human epidermal growth factor receptor 2 · Metastatic breast
cancer · Trastuzumab
Abbreviations
AE	Adverse event
AR	Androgen receptor
AR+	Androgen receptor-positive
BMI	Body mass index
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BORR	Best overall response rate
CBR24	Clinical benefit rate at 24 weeks
CI	Confidence interval
CR	Complete response
ECOG	Eastern Cooperative Oncology Group
EES	Efficacy evaluable set
ER	Estrogen receptor
FAS	Full analysis set
FISH	Fluorescence in situ hybridization
HER2	Human epidermal growth factor receptor 2
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HER2+	Human epidermal growth factor receptor
2-positive
HR	Hormone receptor
MBC	Metastatic breast cancer
NA	Data not available
NCI CTCAE	National Cancer Institute Common Terminology Criteria for Adverse Events
ORR	Overall response rate
PFS	Progression-free survival
PgR	Progesterone receptor
PR	Partial response
RECIST	Response Evaluation Criteria in Solid
Tumors
SAF	Safety analysis set
SD	Stable disease
T-DM1	Trastuzumab emtansine
TEAE	Treatment-emergent adverse event
TTP	Time to progression
TTR	Time to response

Introduction
Breast cancer is among the most frequently diagnosed
malignancies and the second most common cause of cancer
deaths in women worldwide, with an estimated 1.67 million
new cases diagnosed globally in 2012 [1]. Breast cancer,
including metastatic breast cancer (MBC), is a heterogeneous disease, making its prognosis and management complex.
While the 5-year relative survival rate is 99% for patients
presenting with localized disease, it is only 27% for patients
with MBC [2]. Human epidermal growth factor receptor 2
(HER2) is amplified/overexpressed in approximately 15% of
all breast cancer cases [3], making treatment recommendations for MBC highly dependent on hormone receptor (HR)
and HER2 status [3, 4]. Survival for patients with HER2positive (HER2+) MBC has been significantly prolonged
due to anti-HER2 therapies [5–9].
The recommended first-line treatment for HER2+ MBC is
chemotherapy plus dual HER2 inhibition with trastuzumab
and pertuzumab [3, 4]. Trastuzumab emtansine (T-DM1) is
recommended over lapatinib plus capecitabine as standard
second-line therapy after trastuzumab-based first-line treatment [4]. In practice, the anti-HER2 agent selected depends
on country-specific availability, previous anti-HER2 therapy,
and time to relapse [4, 10]. However, even with full access to
anti-HER2 agents, the vast majority of patients will eventually experience disease progression. Thus, there remains an
unmet medical need in HER2+ MBC treatment for effective
new therapies [3, 4].
Androgen receptor (AR) expression is observed in up to
86% of HER2+ breast cancers [11–13] and has been investigated as a potential therapeutic target in breast cancer. The

13

Breast Cancer Research and Treatment (2021) 187:155–165

AR-signaling inhibitor enzalutamide [14] is either approved
or under regulatory consideration for approval for castration-resistant prostate cancer, irrespective of the presence
of metastases, and metastatic castration-sensitive prostate
cancer (also known as metastatic hormone-sensitive prostate
cancer) around the world [15–17]. Enzalutamide enhances
the in vitro antitumor activity of trastuzumab in trastuzumab-resistant HER2+ cell lines [18], warranting clinical
investigation of whether inhibiting AR in HER2+ breast
cancers in combination with currently available anti-HER2
therapeutics could improve patient outcomes. We therefore
evaluated the efficacy and safety of combining the antiHER2 therapy trastuzumab with enzalutamide in patients
with HER2+ AR+ locally advanced breast cancer or MBC.

Patients and methods
Study design
This was a multinational, multicenter, open-label, singlearm, two-stage, phase II trial evaluating the efficacy, safety,
and tolerability of enzalutamide in combination with trastuzumab (NCT02091960). The study was approved by an
independent ethics review board at each participating site
or by national authorities and was conducted according to
the provisions of the Declaration of Helsinki and the Good
Clinical Practice Guidelines of the International Council for
Harmonisation of Technical Requirements for Registration
of Pharmaceuticals for Human Use.

Study population
Eligible patients were women aged ≥ 18 years with histologically or cytologically proven HER2+ AR+ breast carcinoma
(see Online Resource 1: Patients and methods). Inclusion
in the study could be based on local or central pathology
assessment. Patients with locally assessed breast cancer
also had their samples sent for central pathology laboratory
assessment. Patients were allowed to remain in the study
if subsequent central assessment did not confirm locally
assessed AR+ breast carcinoma.
Inclusion criteria of the study included the following:
(i) metastatic or locally advanced disease that was not
amenable to curative treatment and had to have measurable or non-measurable, evaluable disease per Response
Evaluation Criteria in Solid Tumors (RECIST) v1.1 [19],
(ii) previous treatment with ≥ 1 line of anti-HER2 therapy
in the metastatic or locally advanced disease setting, (iii)
documented progression or discontinued the most recent
anti-HER2 therapy due to investigator decision or toxicity
other than cardiotoxicity, and (iv) an Eastern Cooperative
Oncology Group performance status ≤ 1 and a minimum life
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expectancy of ≥ 6 months. Exclusion criteria included (i)
severe concurrent disease, (ii) severe infection or significant
comorbidity, (iii) known or suspected brain metastases or
active leptomeningeal disease, (iv) a history of a non-breastcancer malignancy, (v) inadequate marrow, hepatic, and/or
renal function, (vi) a history of seizures, and (vii) clinically
significant cardiovascular disease.

Analysis sets
The safety analysis set (SAF) included all enrolled patients
who received at least one or a partial dose of study treatment. The full analysis set (FAS) was defined as all patients
in the SAF who had centrally assessed AR+ breast cancer
(defined as ≥ 10% of tumor cells with nuclear expression).
The efficacy evaluable set (EES) included all patients in
the FAS who had at least one available post-baseline tumor
assessment. The primary analysis was performed in the EES,
while all efficacy analyses were performed in both the EES
and FAS. Patient disposition and safety were based on SAF.

Treatments
Patients received a once-daily oral dose of 160 mg enzalutamide (4 × 40 mg capsules) and trastuzumab, starting with
a loading dose (8 mg/kg) followed by either intravenous
(6 mg/kg) or subcutaneous (600 mg/5 mL) administration
every 21 days. Dose interruptions or modifications of enzalutamide and trastuzumab were permitted due to toxicity,
as defined in the study protocol (see Online Resource 1:
Patients and methods). Patients continued on treatment until
disease progression, unacceptable toxicity, or any other discontinuation criteria were met.

Study end points
Primary end point was clinical benefit rate at 24 weeks
(CBR24), defined as the proportion of evaluable patients
with best objective response of confirmed complete response
(CR) or partial response (PR) per RECIST v1.1 or prolonged
stable disease (SD) ≥ 24 weeks. Key secondary end points
were best overall response rate (BORR; CR or PR), overall
response rate (ORR; CR or PR) at 24 weeks, progressionfree survival (PFS), time to progression (TTP), time to
response (TTR), and safety. Prespecified exploratory end
points included CBR24 in subgroups by AR-expression levels, hormone receptor (HR) status, and lines of prior therapy.

Assessments
Radiographic disease assessments according to RECIST
v1.1 [19] were performed by the investigator at baseline and
every 8 weeks up to week 49, then every 12 weeks thereafter.
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Local AR testing results were confirmed centrally using the
Ventana Assay (Ventana Medical Systems, Inc., Tucson,
USA) (see Online Resource 1: Patients and methods). Safety
assessments throughout the study included the recording
of adverse events (AEs). Cardiac safety assessments were
required throughout the study to monitor for trastuzumabassociated cardiotoxicity (see Online Resource 1: Patients
and methods).

Statistical analysis
The study followed an optimal Simon’s two-stage design to
determine sample sizes. A CBR24 of ≥ 3 out of 21 evaluable
patients was required in stage I to continue to stage II. In
total, approximately 80 patients were planned to be enrolled
to achieve a dataset with at least 66 evaluable AR+ patients.
The null hypothesis that the true CBR24 is ≤ 10% was tested
against a one-sided alternative at a 5% significance level.
This design has a statistical power of 90% when the true
CBR24 is 25%. Patients in the FAS were included in primary
and secondary efficacy analyses. See Online Resource 2:
Statistical analysis for descriptive statistics. CBR, BORR,
and ORR are summarized, including 95% two-sided exact
confidence intervals (CIs) (Clopper–Pearson method).
Kaplan–Meier analyses were used to estimate the median
PFS, TTP, and TTR.

Results
This trial was conducted in 35 centers in six countries
(Belgium, Canada, Italy, Spain, United Kingdom, and
United States). Between September 2014 and August
2016, 103 patients were enrolled and received at least
one dose of enzalutamide and trastuzumab (see Online
Resource 3: Fig. S1). The actual enrollment was greater
than the planned enrollment goal of 80 patients due to
increased screening and patient recruitment. At the end
of stage I, six out of 22 evaluable patients (27%; 95%
CI 10.7–50.2) demonstrated CBR24, thus meeting the
prespecified requirement for the study to continue to
stage II.
Baseline patient demographics and disease characteristics
are reported in Table 1. In the efficacy evaluable set, approximately 52% of patients were HR + and 87% were perimenopausal or post menopausal. All patients had been previously
treated with trastuzumab, and 62% had received ≥ 3 lines of
prior anti-HER2 therapy. HER2 status was locally determined. Local AR testing results were confirmed centrally
using the Ventana Assay, with a concordance level of 98.6%
(see Online Resource 4: Table S1). AR staining was high
(i.e., 50–100% positive cells) in approximately 90% of
patients.
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Table 1  Patient demographics
and baseline characteristics
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Safety analysis s eta
(n = 103)
Age (years)
Median (range)
60.0 (34–83)
Age categories (years), n (%)
≤ 65
78 (76)
66–75
18 (18)
> 75
7 (7)
BMI (kg/m2)
Median (range)
25.7 (14–50)
Ethnicity, n (%)
Not Hispanic or Latino
98 (95)
Hispanic or Latino
5 (5)
Race, n (%)
White
90 (87)
Black or African-American
8 (8)
Asian
3 (3)
Other
2 (2)
ECOG performance status at baseline, n (%)
0
51 (49)
1
51 (49)
Unknown
1 (1)
Time from initial diagnosis to enrollment (days)
n
95
Median; minimum, maximum
1199; 30, 4713
HER2 status, n (%)d
Positive
89 (86)
Negative
2 (2)
Unknown
12 (12)
HER2 testing method confirming HER2 status, n (%)d
Immunohistochemistry
35 (34)
In situ hybridization
27 (26)
HER2 amplification
22 (21)
Unknown
19 (18)
HR status, n (%)
51 (49)
Positivee
Negative
38 (37)
Unknown
14 (14)
AR + from Ventana Assay, n (%)
> 0– < 10%
2 (2)
10– < 50%
8 (8)
50–100%
88 (90)
Unknown
5
Lines of prior antineoplastic therapy, n (%)f
1
14 (13)
2
20 (19)
3
11 (11)
4
12 (12)
>4
46 (45)
Lines of prior anti-HER2 therapy, n (%)
1–2
NA
3–4
NA
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Full analysis s etb
(n = 96)

Efficacy evaluable setc (n = 89)

60.0 (34–83)

60.0 (34–83)

73 (76)
17 (18)
6 (6)
25.7 (14–50)

66 (74)
17 (19)
6 (7)
25.6 (14–50)

91 (95)
5 (5)

84 (94)
5 (6)

83 (87)
8 (8)
3 (3)
2 (2)

78 (88)
6 (7)
3 (3)
2 (2)

49 (51)
46 (48)
1 (1)

47 (53)
42 (47)
0

89
1321; 30, 4713

83
1340; 30, 4713

83 (86)
2 (2)
11 (12)

77 (87)
2 (2)
10 (11)

33 (34)
25 (26)
21 (22)
17 (18)

30 (34)
24 (27)
19 (21)
16 (18)

48 (50)
35 (36)
13 (14)

46 (52)
31 (35)
12 (14)

0

0

8 (8)
88 (92)
0

7 (8)
82 (92)
0

13 (14)
17 (18)
10 (10)
12 (12)
44 (46)

13 (15)
15 (17)
10 (11)
11 (12)
40 (45)

NA
NA

33 (37)
24 (27)
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Table 1  (continued)

≥5
Menopausal status,g n (%)
Premenopausal
Perimenopausal
Post menopausal
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Safety analysis s eta
(n = 103)

Full analysis s etb
(n = 96)

NA

NA

13 (12)
13 (12)
77 (76)

12 (12)
12 (12)
72 (76)

Efficacy evaluable setc (n = 89)
31 (35)
12 (13)
12 (13)
65 (74)

AR androgen receptor, BMI body mass index, ECOG Eastern Cooperative Oncology Group, ER estrogen
receptor, FISH fluorescence in situ hybridization, HER2 human epidermal growth factor receptor 2, HR
hormone receptor, NA data not available, PgR progesterone receptor
a

b

All enrolled patients who received at least one or a partial dose of study treatment

All patients in the safety analysis set who had centrally assessed AR+ breast cancer (defined as ≥ 10% of
tumor cells with nuclear expression)

c

d

All patients in the full analysis set who had at least one available post-baseline tumor assessment

Local HER2 testing method from most recent biopsy (all patients had at least one biopsy with HER2+ status)
e
f

Positive HR status = ER+ and PgR+ or ER− and PgR+ or ER+ and PgR−

Includes all therapies in the settings of locally advanced and metastatic disease and recurrence. It excludes
adjuvant and neoadjuvant therapy

g

Post-menopausal status was defined as no spontaneous menses for ≥ 12 months with FISH > 40 IU/L for
patients aged < 55 years, documented surgically sterile, or ≥ 1 month post hysterectomy prior to screening

The median duration of exposure for enzalutamide
was 70 days (range 1–660). Patients received a median
of four trastuzumab infusions (see Online Resource 5:

Table S2). At the time of data cut-off (February 2017), 12
(12%) patients remained on treatment.

Table 2  Tumor response
Efficacy end point

Efficacy evaluable s eta (n = 89)

Full analysis set (n = 96)

CBR24 (CR or PR or prolonged SD > 24 weeks), n [% (95% CI)]
Best overall response,b n (%)
CR
PR
SD
Durable SD at ≥ 24 weeksc
Progressive disease
Not evaluable
Best overall response rate (CR or PR), n [% (95% CI)]
Overall response rate at 24 weeks (CR or PR), n [% (95% CI)]
Time to progression (days),f median (95% CI)
Time to response (days),g median (range)

21 [23.6 (15.2–33.8)]

21 [21.9 (14.1–31.5)]

0 (0)
4 (5)
42 (47)
17 (19)
42 (47)
1 (1)
4 [4.5 (1.2–11.1)]
3 [3.4 (0.7–9.5)]
108.0 (61–116)
57.0 (57–222)

0 (0)
4 (4)
42 (44)
17 (18)
42 (44)d
1 (1)e
4 [4.2 (1.1–10.3)]
3 [3.1 (0.6–8.9)]
108.0 (61–116)
57.0 (57–222)

CBR24 clinical benefit rate at 24 weeks, CI confidence interval, CR complete response, FAS full analysis set, PR partial response, RECIST
Response Evaluation Criteria in Solid Tumors, SD stable disease
a

b
c
d
e
f

Primary efficacy analysis set
Best overall response per RECIST v1.1 (CR, PR, SD, progressive disease, and not evaluable)
Durable SD is a subset of SD
Excludes 5 of 7 patients in the FAS with progressive disease but no post-baseline tumor radiographic assessments
Excludes 7 patients without post-baseline tumor assessments who are in the FAS

Time to progression is defined as the time from the first date of enzalutamide treatment until the date of disease progression per RECIST v1.1

g

Time to response is defined as the time from the first date of enzalutamide treatment to initial CR or PR
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100
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overall response of SD. BORR was 5% and ORR at
24 weeks was 3%. Median TTR and TTP were 57.0 days
(range 57–222) and 108.0 days (95% CI 61–116), respectively. Median PFS was 3.4 months (95% CI 2.0–3.8)
(Fig. 1a). A plot of response to treatment for individual
patients is shown in Fig. 1b.

Enzalutamide and trastuzumab
Censored
N of events: 74/96

90
80
70
60
50

Median =
3.4 months
(95% CI
2.0–3.8)

40
30
20

Exploratory efficacy subgroup analyses

10
0

0

1

2

3

4

5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Time since treatment initiation (months)

N at risk
92 89 50 43 26 23 16 15

9

9

In exploratory analyses of efficacy in subgroups defined
by AR-expression level (percentage of tumor cells with
nuclear expression) and by HR status (HR + or HR−),
CBR24 was similar in all subgroups versus the overall
patient population (see Online Resource 6: Table S3).
Additionally, efficacy did not appear to be affected by the
number of previous lines of antineoplastic therapy or antiHER2 therapy (see Online Resource 7: Table S4).

5

b
+
+
+

Days on treatment
Follow-up
+ Censored observation
Progressive disease
Start of other new antineoplastic therapy
Partial response
Stable disease
# Death

#

#
#
+

+

+

Safety
Individual patients

+

+
+

#
+

+
+

#
+

+
+
+
+

+

+
+
+

0

2

4

6

8

10

12

14

16

18

20

22

Time since treatment initiation (months)

Fig. 1  a Kaplan–Meier curve of progression-free s urvivala in the full
analysis set; b swimmer plot of response to treatment for individual
patients aProgression-free survival is defined as the time from the
date of first dose of enzalutamide until the date of disease progression per RECIST v1.1 or death from any cause on study (death within
168 days after treatment discontinuation), whichever occurred first
CI confidence interval, RECIST Response Evaluation Criteria in
Solid Tumors

Efficacy
In the primary efficacy analysis set, CBR24 was 24%
(21/89 patients) (Table 2). Four (5%) patients had confirmed PR and 17 (19%) patients had durable SD at
24 weeks. Additionally, 42 (47%) patients had a best
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Treatment-emergent adverse events (TEAEs) of any grade
were reported in 97 (94%) patients; the most common
(≥ 10%) included fatigue in 35 (34%) and nausea in 28
(27%) patients (Table 3). Dyspnea (four patients = 4%)
and malignant neoplasm progression due to breast cancer
(three patients = 3%) were the only TEAEs of grade ≥ 3
reported in ≥ 3 patients. Serious TEAEs were reported
in 22 (21%) patients; the most frequent (≥ 2.0%) were
malignant neoplasm progression due to breast cancer
(five patients = 5%), nausea (three patients = 3%), and
vomiting (three patients = 3%). Four patients (4%) experienced fatal TEAEs: (i) two malignant neoplasm progression, (ii) one pulmonary edema, and (iii) one general
physical health deterioration associated with concurrent
worsening abdominal pain and dyspnea. None of these
fatal AEs were assessed as related to a study drug.
Enzalutamide- or trastuzumab-related TEAEs occurred
in 78 (76%) patients (Table 3). Eight serious enzalutamiderelated TEAEs, nausea (two events), vomiting, diarrhea,
dyspepsia, asthenia, accidental overdose, and dyspnea,
were reported in three (3%) patients; no trastuzumabrelated serious TEAEs were reported. Drug-related TEAEs
necessitating dose reduction of enzalutamide occurred in
seven (7%) patients (see Online Resource 5: Table S2), the
most frequent being fatigue (three patients = 3%). Studydrug-related TEAEs led to permanent discontinuation of
enzalutamide in five (5%) and of trastuzumab in four (4%)
patients (Table 3).

Breast Cancer Research and Treatment (2021) 187:155–165
Table 3  Treatment-emergent
adverse events
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Event, n (%)

Safety analysis
set (n = 103)

Total number of TEAEs
Serious TEAEs
Enzalutamide- or trastuzumab-related TEAEs
Enzalutamide-related TEAEs
Trastuzumab-related TEAEs
Serious (enzalutamide-related) TEAEs
TEAE leading to permanent discontinuation of enzalutamide or trastuzumab
Study-drug-related TEAEs leading to permanent discontinuation of enzalutamide
Study-drug-related TEAEs leading to permanent discontinuation of trastuzumab
Deaths
Any grade TEAE (≥ 10% patients)a,b
Fatigue
Nausea
Hot flush
Decreased appetite
Dyspnea
Back pain
Dizziness
Headache
Constipation
Diarrhea
Arthralgia
Pain in extremity
Vomiting
Grade ≥ 3 (≥ 2 patients)a,b
Dyspnea
Abdominal pain
Back pain
Fatigue
Malignant neoplasm progression–breast cancer
Pneumonia
Thrombocytopenia
Vomiting

97 (94)
22 (21)
78 (76)
75 (73)
39 (38)
3 (3)
21 (20)
5 (5)
4 (4)
4 (4)
35 (34)
28 (27)
17 (17)
15 (15)
15 (15)
14 (14)
14 (14)
14 (14)
13 (13)
13 (13)
12 (12)
11 (11)
11 (11)
4 (4)
2 (2)
2 (2)
2 (2)
3 (3)
2 (2)
2 (2)
2 (2)

NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events, TEAE treatment-emergent adverse event

a

b

NCI CTCAE grade (v4.03)
By preferred term

Discussion
In this single-arm phase II study of enzalutamide plus
trastuzumab in heavily pretreated patients with advanced
HER2+ AR+ breast cancer, CBR24 was 24% in the primary
analysis set, with a BORR of 5%. Overall, a median PFS of
3.4 months was observed.
Direct comparisons cannot be made across different clinical studies due to the heavily pretreated nature
and specific AR+ subset of the HER2+ MBC patient

population in this study, for which equivalent data are
scarce. In a study with HER2+ locally advanced/MBC
patients who had received a median of three trastuzumab
regimens, lapatinib in combination with trastuzumab
showed an ORR of 10.3% compared to 6.9% for lapatinib
alone [6]. In the TH3RESA study of T-DM1 in patients
who had previously received ≥ 2 HER2-directed regimens
in the advanced setting, including trastuzumab and lapatinib, median PFS (T-DM1 = 6.2 months versus physicians’ choice = 3.3 months) was higher than in the current
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study for T-DM1, although the patient populations are not
directly comparable [20]. Overall, the combination of trastuzumab plus enzalutamide appears to offer durable disease control in a subset of patients with heavily pretreated
HER2+ AR+ MBC; however, the clinical impact of this
observation is limited because those patients most likely
to benefit could not be identified in advance.
The interpretation of these efficacy results should take
into account the heavily pretreated patient population in
this study (> 60% having received ≥ 3 previous lines of
anti-HER2 therapy), although the number of previous lines
of anti-HER2 therapy did not appear to be associated with
CBR24. In this study, AR-expression levels and HR status
did not appear to predict benefit of the combination. However, preclinical data suggest that AR plays a differential
role in tumor suppression and oncogenesis within ER+ and
ER− breast tissue, respectively [21]. The use of more
sophisticated analyses of endocrine signaling may reveal the
interaction of HR status and AR in HER2+ MBC in future
trials. Current treatments for HER2+ MBC are based on
anti-HER2 therapies [3, 4]; however, there remains a need
for new targeted treatments with predictive biomarkers to
identify patient subgroups that are most likely to respond,
including patients with HER2+ AR+ MBC. Indeed, multiple new treatments are being evaluated for HER2+ MBC,
including cyclin D-dependent kinase 4/6 inhibitors, tyrosine kinase inhibitors, phosphoinositide 3-kinase inhibitors,
mammalian target of rapamycin inhibitors, immunotherapies, antibody drug conjugates, monoclonal antibodies, and
therapeutic dendritic cell-based vaccines [22, 23].
In this study, enzalutamide showed a favorable safety profile, consistent with that seen in men with prostate cancer
[17] and women with AR-expressing, triple-negative breast
cancer [24]. No new safety signals were observed in this
female breast cancer population. The frequencies of the most
common enzalutamide-related TEAEs in this study, fatigue
(30%) and nausea (20%), were in line with those reported in
previous enzalutamide trials in men.
This study had limitations. It was a single-arm study
consisting of a heterogenous population and, consequently,
direct comparison of the efficacy and safety results of enzalutamide plus trastuzumab with other therapies is not possible. Moreover, information that may have assisted in the
exploratory analyses to identify predictive biomarkers, such
as further details of local genetic testing (e.g., HER2 gene
copy number and fluorescence in situ hybridization ratio)
and definitions of local estrogen receptor and/or progesterone receptor positivity, were not collected. Importantly,
we were unable to centrally assess 24 locally reviewed
AR+ cases and 11 HER2+ cases due to a lack of sample
material.
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Conclusions
The combination of enzalutamide and trastuzumab was well
tolerated, and a subset of patients derived durable disease
control. Determination of biomarkers to identify patients
most likely to benefit from this combination are needed for
this intervention to have a meaningful clinical impact.
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